Idose Tr Implant
NDC Package 25357-100-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

Idose Tr (travoprost intracameral) implants is travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e.g., ocular hypertension). This formulation utilizes a implant delivery system. Marketed by Glaukos Corporation, this product is identified by NDC 25357-100 and is authorized under FDA application NDA218010.

Identification & Billing

NDC Package Code
25357-100-01
Package Description
1 POUCH in 1 CARTON / 1 TRAY in 1 POUCH / 1 CANISTER in 1 TRAY / 1 IMPLANT in 1 CANISTER
Product Code
25357-100
11-Digit Billing Format
25357010001
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Idose Tr
Non-Proprietary Name
Travoprost Intracameral
Substance Name
Travoprost
Dosage Form
Implant - A material containing drug intended to be inserted securely of deeply in a living site for growth, slow release, or formation of an organic union.
Active Ingredient(s)
TRAVOPROST 75 ug/1
Pharmacologic Class
Usage Information
Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e.g., ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Regulatory & Marketing

Labeler Name
Glaukos Corporation
Product Type
Human Prescription Drug
FDA Application #
NDA218010
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-13-2023
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J7355
Source: ASP
Inj travoprost intra impl
HCPCS Dosage 1 MCG
Units / Pkg 75

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (25357-100). Click a package code to view its specific billing and regulatory data.

25357-100-99
1 POUCH in 1 CARTON / 1 TRAY in 1 POUCH / 1 CANISTER in 1 TRAY / 1 IMPLANT in 1 CANISTER

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 25357-100-01 identifies a specific commercial package of 1 pouch in 1 carton / 1 tray in 1 pouch / 1 canister in 1 tray / 1 implant in 1 canister of Idose Tr, a human prescription drug labeled by Glaukos Corporation. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This implant is formulated for intracameral use and contains travoprost as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glaukos Corporation on December 13, 2023. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e.g., ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

How is this Glaukos Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 25357010001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
25357-100-01
11-Digit CMS (5-4-2)
25357-0100-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.